CMPS // COMPASS Pathways Plc American Depository Shares
FA <GO> NASDAQ RQD COCKPIT → CIK 0001816590 ↗ Health Care • Biotechnology: Pharmaceutical Preparations
$12.19 ▼ -0.09
(-0.73%)
MKT CAP: $1.69B • VOL: 1.38M
52W L $5 52W H $16
ROARABLE / RQD
D- • 37/100
PIOTROSKI
1 / 9
CMPS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$179.0M | -$178.2M | -$136.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$269.8M | -$155.1M | -$118.5M |
| EBITDA (Normalized) | — | -$178.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$157.2M | -$119.2M | -$97.4M |
| Capital Expenditures (CapEx) | — | $0 | — |
| Free Cash Flow (FCF) | -$157.2M | -$119.2M | -$97.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $149.6M | $165.1M | — |
| Total Debt (Short + Long Term) | $14.1M | $24.7M | — |
| Total Stockholders' Equity | -$52.8M | $154.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CMPS.